Yang W, et al. - In 543 Chinese adults with type 2 diabetes inadequately controlled on premix/self-mix or basal insulin ± metformin, researchers tested the safety and effectiveness of twice-daily (BID) insulin degludec/insulin aspart (IDegAsp) vs biphasic insulin aspart 30 (BIAsp 30) BID, both ± metformin. According to findings, estimated rates of nocturnal confirmed and total confirmed hypoglycemic episodes with IDegAsp BID vs BIAsp 30 BID were 47% and 43% lower, respectively. There was no confirmation of superiority for change in body weight. Patients with IDegAsp BID vs BIAsp 30 BID were more likely to reach HbA1c < 7.0% by the trial end without confirmed hypoglycemia. No new safety signals were identified.